These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1664295)

  • 41. [Response of revaccination against polio I in seronegative children after receiving 3 or more doses of the vaccine].
    Ruiz-Gómez J; Sánchez Burgos Y; Arrayales Sandoval F; Velázquez Zúñiga C
    Gac Med Mex; 1977 Jan; 113(1):23-7. PubMed ID: 863152
    [No Abstract]   [Full Text] [Related]  

  • 42. Eradication of poliomyelitis in Cuba: a historical perspective.
    Más Lago P
    Bull World Health Organ; 1999; 77(8):681-7. PubMed ID: 10516790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Serum conversion rate following oral poliomyelitis immunization in Mali, Africa 1982].
    Ehrengut W; AgRhaly A; Koch I; Koumaré B; Simaga SY; Diallo D
    Monatsschr Kinderheilkd; 1984 Jan; 132(1):29-31. PubMed ID: 6321963
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EPI vaccines-induced antibody prevalence in 8-9 year-olds in The Gambia.
    Viviani S; Mendy M; Jack AD; Hall AJ; Montesano R; Whittle HC
    Trop Med Int Health; 2004 Oct; 9(10):1044-9. PubMed ID: 15482396
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current status of polio immunization, with recent legal implications.
    Van Reken DE
    J Fam Pract; 1976 Dec; 3(6):603-5. PubMed ID: 1003132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serosurvey for polio antibodies.
    Biberi-Moroeanu S; Munţiu A; Stoiculescu S
    Virologie; 1988; 39(4):241-5. PubMed ID: 2851206
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials.
    John TJ; Jain H; Ravishankar K; Amaresh A; Verma H; Deshpande J; Pallansch MA; Singh AP; Sreevatsava M; Burton A; Malankar P; Chatterjee A; Sutter RW
    Vaccine; 2011 Aug; 29(34):5793-801. PubMed ID: 21641951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa.
    Waggie Z; Geldenhuys H; Sutter RW; Jacks M; Mulenga H; Mahomed H; De Kock M; Hanekom W; Pallansch MA; Kahn AL; Burton AH; Sreevatsava M; Hussey G
    J Infect Dis; 2012 Jan; 205(2):228-36. PubMed ID: 22158680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The effect of aluminum adjuvant and immunization schedule on immunogenicity of Sabin inactivated poliovirus vaccine].
    Wang F; Zhang M; Xie BF; Cao H; Tong SY; Wang JR; Yu XP; Tang Y; Yang JR; Sun MB
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr; 27(2):102-4. PubMed ID: 24044212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Implementing secondary poliomyelitis vaccination].
    Pietsch R; Riegel H
    Gesundheitswesen; 1992 Dec; 54(12):714-5. PubMed ID: 1366256
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-lasting poliovirus-neutralizing antibodies among Argentinean population immunized with four or five oral polio vaccine doses 1 month to 19 years previously.
    Nates SV; Martinez LC; Barril PA; Ferreyra LJ; Giordano MO; Masachessi G; Isa MB
    Viral Immunol; 2007; 20(1):3-10. PubMed ID: 17425416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic and mucosal immune response to polio vaccination with additional dose in newborn period.
    Bhaskaram P; Nair KM; Hemalatha P; Murthy N; Nair P
    J Trop Pediatr; 1997 Aug; 43(4):232-4. PubMed ID: 9283127
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Poliovirus neutralising antibody in infants and cord blood.
    Yin-Murphy M; Tan KL; Lim GN; Quek JH; Ishak B; Phoon MC
    Ann Acad Med Singap; 1993 May; 22(3):281-5. PubMed ID: 8396883
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Humoral antibodies, coproantibodies and viral excretion in newborn infants immunized with poliomyelitis vaccine].
    Ruíz-Gómez J; Caloca García MA; Longega Escobio P
    Salud Publica Mex; 1979; 21(2):127-34. PubMed ID: 231330
    [No Abstract]   [Full Text] [Related]  

  • 56. [Development of immunity to the poliomyelitis virus in infants with various methods of administering a live poliomyelitis vaccine].
    Drozdov SG; Zhevandrova VI; Smirnova GA; Shmel'kov IuA; Kodkind GKh
    Vopr Virusol; 1979; (3):252-9. PubMed ID: 223328
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 50 Years Ago in the Journal of Pediatrics: Oral Polio Immunization of the Newborn Infant; A Possible Method for Overcoming Interference by Ingested Antibodies.
    Toltzis P
    J Pediatr; 2018 Aug; 199():177. PubMed ID: 30049392
    [No Abstract]   [Full Text] [Related]  

  • 58. Gap in the prevalence of neutralising antibodies to polioviruses in antenatal women in southern India.
    John J; Abraham AM; Muliyil J; John TJ; Deshpande JM; Kang G
    Trans R Soc Trop Med Hyg; 2011 Mar; 105(3):179-80. PubMed ID: 21277608
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reasons for partial/non-immunization with oral polio vaccine/triple antigen among children under five years.
    Devivanayagam N; Nedunchelian K; Ashok TP; Mala N
    Indian Pediatr; 1992 Nov; 29(11):1347-51. PubMed ID: 1294488
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expanded programme on immunization. Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population.
    Wkly Epidemiol Rec; 1992 Jun; 67(24):179-82. PubMed ID: 1319191
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.